We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Test to Advance Targeted Treatments for Childhood Cancer

By LabMedica International staff writers
Posted on 03 Mar 2025

Researchers have developed a simple blood test that could offer deeper insights into childhood cancers, potentially leading to the development of more targeted and less toxic treatments. More...

A research team from The Institute of Cancer Research (ICR, London, UK) has been working to create a less invasive method for tracking how childhood tumors evolve and respond to treatment. Recent findings from the Stratified Medicine Pediatrics (SMPaeds1) program, published in Cancer Discovery, show that circulating tumor DNA (ctDNA) testing can provide a more comprehensive view of how a tumor progresses over time. In the study, the team examined both childhood tumor samples taken at the initial diagnosis and ctDNA—fragments of tumor DNA found in the blood—during relapse to understand how tumors adapt after treatment. In certain cases, the test even detected additional DNA mutations that were not identified in the original tumor biopsy.

Since ctDNA testing only requires a blood sample, it is far less invasive than a traditional tumor biopsy, which often requires a general anesthetic. These findings are expected to advance the understanding of why some tumors relapse or fail to respond to treatment, with the ultimate goal of developing more effective, targeted therapies. The second phase of the research program (SMPaeds2) is now underway, with plans to further refine and explore new tests building on the success of the first phase. SMPaeds2 will focus on blood cancers and solid tumors in children and young people, including those affecting the brain, muscle, and bone, which are often more difficult to diagnose and treat.

“We showed that ctDNA analysis can add valuable information and that in some patients it can detect additional DNA mutations that are in the tumor but were missed by tumor biopsy,” said study author Dr. Sally George, Group Leader of the Developmental Oncology group at ICR. “SMPaeds1 is the largest study with matched ctDNA and tissue sequencing to date and shows the value of ctDNA testing for children with cancer. We are working with colleagues across Europe to transition ctDNA analysis from being a research test to being available clinically. The project also identifies DNA mutations that become enriched at relapse. This will help us prioritize future research to understand why those mutations are enriched and if we can develop new treatments to target cancers with those mutations.”


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.